Skip to main content
Premium Trial:

Request an Annual Quote

Chronix, U of Calgary to Develop Mad Cow Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chronix Biomedical and the University of Calgary have partnered to develop a commercial version of a serum DNA-based test for early detection of bovine spongiform encephalopathy (BSE), commonly called mad cow disease, Chronix said today.

Chronix is developing a diagnostic, monitoring, and management testing technology that can identify and analyze DNA fragments circulating in the bloodstream. The firm published data in 2009 showing that these techniques could be used to detect BSE in cattle before disease symptoms show.

The BSE assay development project is supported by a grant from Genome Canada and the Alberta Livestock and Meat Agency. Chronix said that it expects to begin offering the BSE testing service to the cattle industry once the commercial test is finalized and validated.

The BSE test will be the first commercial application of the Chronix technology, which is generally being developed for detecting and monitoring human diseases such as cancer and chronic conditions.

"This effort is critically important because the risk of introducing BSE into the food chain continues to worry consumers and hinder international trade," University of Calgary Professor Christoph Sensen said in a statement.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.